Gastroenterologie a hepatologie
type: channel
description: Gastroenterology and Hepatology is an official peer-reviewed journal of the Czech Society of Gastroenterology and the Czech Society of Hepatology, the Slovak Society of Gastroenterology and the Slovak Society of Hepatology, published by the Czech Medical Association of J. E. Purkyně by the publishing house Care Comm. It is published on 6× a year. The articles are published in Czech, Slovak and English. The journal has been published since 1999, its previous name was Czech and Slovak Gastroenterology and Hepatology (ISSN 1213-323X). Gastroenterology and hepatology are indexed in the following databases: SCOPUS, CHEMICAL TITLES, EXCERPTA MEDICA/EMBASE, CHEMICAL ABSTRACTS, INIS Atomindex, Food Science and Technology Abstracts, Bibliographia Medica Čechoslovaca, Index Copernicus.
publisher: Česká lékařská společnost JEP
language: en
publication name: Gastroenterologie a hepatologie
issn: 1804-7874
items: Mapping the treatment landscape for ulcerative colitis in the era of IL-23 inhibitors
items: Three different approaches to subcutaneous infliximab: an in-depth look
items: Subcutaneous infliximab – improving treatment outcomes for patients with IBD
items: Správná odpověď na předchozí kvíz
items: The selection from international journals 2/2026
items: Milestones in the research, development, and therapeutic use of infliximab
items: Potential therapeutic targets for the treatment of inflammatory bowel dis­eases
items: Impact of successful iron deficiency anemia correction with iron carboxymaltose on quality of life, treatment adherence, and exacerbation frequency in inflammatory bowel dis­ease patients
items: Dia­gnosis and therapy of hepatitis B virus infection: Czech national guidelines
items: A rare cause of headache in a liver transplant patient – a case report
items: Neutrophil-to-lymphocyte ratio reflects inflammatory phenotypes of alcohol-associated hepatitis: differences between mild and severe dis­ease
items: Donation after Circulatory Death (DCD) – The Need for Programme Implementation in Slovakia
items: Benefits and risks of HCV cure
items: Editorial 2/2026
items: Let‘s go beyond the limits of Crohn‘s disease treatment – simply, subcutaneously
items: The time has come for a paradigm shift in the care of patients with IBD in the Czech Republic
items: The selection from international journals 1/2026
items: Recurrent bleeding from a Dieulafoy’s lesion of the cecum – a case report
items: The interplay between oral health and gastrointestinal disorders: a comprehensive narrative review of emerging links and clinical implications
items: Gastrointestinal bleeding in patients with chronic kidney disease
items: Current status and prospects of personalized medicine in patients with inflammatory bowel disease
items: Rare extraintestinal involvement in IBD – a case report
items: Risk of acute pancreatitis in patients with inflammatory bowel disease
items: Subcutaneous infliximab CT-P13 as second-line treatment after failure of anti-TNF therapy in patients with Crohn’s disease
items: Quality of life of patients with inflammatory bowel disease in the Czech Republic
items: Medical therapy of ulcerative colitis: updated guidelines of the Working group for IBD
items: Unexpected cause of overall deterioration in the patient’s condition
items: The sooner, the better
items: Editorial 1/2026
items: 8. kongres České gastroenterologické společnosti: abstrakta

Mapping the treatment landscape for ulcerative colitis in the era of IL-23 inhibitors
type: item
description: Jak mohou nové poznatky o inhibici interleukinu 23 (IL-23) ovlivnit léčbu ulcerózní kolitidy v klinické praxi? Na tuto otázku se zaměřilo satelitní sympozium společnosti Johnson & Johnson na kongresu ECCO 2026, které moderovala prof. Ailsa Hartová ze St Mark’s Hospital v Londýně. Na sympoziu zazněly nové analýzy studie QUASAR zaměřené na guselkumab i zkušenosti z každodenní klinické praxe.
subject: Commercially supported communications
  topic: section
creator: Michaela Bachrata
rights: Copyright (c) 2026
date: 2026-04-17
publication date: 2026-04-17
starting page: 183
ending page: 185
doi: 10.48095/ccgh2026183

Three different approaches to subcutaneous infliximab: an in-depth look
type: item
description: Ke kongresům ECCO patří tradičně i diskuzní setkání s odborníky umožňující v užším kruhu probrat do detailů ně­kte­ré informace prezentované na sympoziích. Navštívili jsme hned tři z nich věnované novým poznatkům o výsledcích subkutánního infliximabu (infliximabu SC) v léčbě pacientů s idiopatickými střevními záněty (IBD) v klinických studiích, ale především v klinické praxi.
subject: Commercially supported communications
  topic: section
creator: Michaela Bachrata
creator: Jan Kulhavy
rights: Copyright (c) 2026
date: 2026-04-17
publication date: 2026-04-17
starting page: 178
ending page: 181
doi: 10.48095/ccgh2026178

Subcutaneous infliximab – improving treatment outcomes for patients with IBD
type: item
description: Role a postavení subkutánního infliximabu (infliximabu SC) v léčbě idiopatických střevních zánětů (IBD) se mění a přesahuje rámec „pouhého“ komfortního podávání. Přibývá důkazů ve prospěch použití infliximabu SC v monoterapii bez imunosupresiv a také o jeho účinnosti v léčbě perianální Crohnovy choroby. Taková byla hlavní témata satelitního sympozia pořádného s podporou společnosti Celltrion 20. února 2026 v rámci programu výročního kongresu Evropské organizace pro Crohnovu chorobu a ulcerózní kolitidu (ECCO) ve Stockholmu.
subject: Commercially supported communications
  topic: section
creator: Jan Kulhavy
rights: Copyright (c) 2026
date: 2026-04-17
publication date: 2026-04-17
starting page: 175
ending page: 177
doi: 10.48095/ccgh2026175

Správná odpověď na předchozí kvíz
type: item
description: Správná odpověď na předchozí kvíz z 1. čísla 2026.
subject: Kvíz z klinické praxe
  topic: section
creator: Ivana Rucklova
rights: Copyright (c) 2026
date: 2026-04-17
publication date: 2026-04-17
starting page: 173
ending page: 173
doi: 10.48095/ccgh2026173

The selection from international journals 2/2026
type: item
description: Články vybrali a komentovali MUDr. Kristýna Zdychyncová1, MUDr. Robert Pospíšil2, MUDr. Mgr. Irena Míková3, doc. MUDr. Lumír Kunovský, Ph.D.4–6, MUDr. Vincent Dansou Zoundjiekpon, Ph.D.4,5 1 Klinické a výzkumné centrum pro střevní záněty, ISCARE a. s. a 1. LF UK, Praha 2 Gastroenterologické oddělení, Nemocnice České Budějovice, a. s. 3 Klinika hepatogastroenterologie, Transplantcentrum, IKEM, Praha 4 II. interní klinika – gastroenterologická a geriatrická LF UP a FN Olomouc 5 Gastroenterologické oddělení a digestivní endoskopie, LF MU a Masarykův onkologický ústav, Brno 6 Chirurgická klinika LF MU a FN Brno
subject: Comments
  topic: section
rights: Copyright (c) 2026
date: 2026-04-17
publication date: 2026-04-17
starting page: 170
ending page: 172
doi: 10.48095/ccgh2026170

Milestones in the research, development, and therapeutic use of infliximab
type: item
description: The chimeric monoclonal antibody against tumour necrosis factor (TNF), for which we now use the generic name infliximab, was developed by J. Le and J. Vilček at New York University School of Medicine in collaboration with Centocor (later Janssen Biotech) under the name cA2. In 1992, M. Feldmann and R. Maini used it in the first proof-of-concept study in rheumatoid arthritis to prove the hypothesis that TNF is at the top of the inflammatory cascade of autoimmune inflammation. In 1998, the US FDA approved it under the trade name Remicade for the treatment of Crohn‘s dis­ease. Between 1999 and 2006, it was registered for the treatment of several other autoimmune dis­eases. The first bio­logically similar medicinal product (bio­similar) was registered in 2014 under the name CT-P13, which was developed by Celltrion. Infliximab has significantly advanced the pharmacotherapy options for autoimmune dis­eases, but it has also contributed to the study of their pathophysiology and to the advancement of bio­logical treatment in general.
subject: Drug profile
  topic: section
subject: infliximab
  topic: keywords
subject: research and development
  topic: keywords
subject: indications
  topic: keywords
subject: clinical trials
  topic: keywords
subject: bio­similars
  topic: keywords
creator: Karel Urbanek
rights: Copyright (c) 2026
date: 2026-04-17
publication date: 2026-04-17
starting page: 161
ending page: 169
doi: 10.48095/ccgh2026161

Potential therapeutic targets for the treatment of inflammatory bowel dis­eases
type: item
description: Research and development of new drugs for the treatment of inflammatory bowel dis­eases focuses on approximately 20 potential pharmacodynamic targets. Most of these are receptors for inflammatory metors and enzymes involved in their function, as well as cytokines themselves. In addition, influencing micro-RNA, immune checkpoints, or an inflammasome appears to be a potential therapeutic option. The most advanced developments to date are in the areas of TL1A cytokine inhibition, microRNA-124 function stimulation, interleukin 6 trans-signalling pathway inhibition, and the type I transforming growth factor β receptor blockade. However, none of the tested targets appear to be entirely specific to the pathophysiology of inflammatory bowel dis­eases, which is a prerequisite for the development of potentially curative pharmacotherapy.
subject: Review article
  topic: section
subject: inflammatory bowel dis­eases
  topic: keywords
subject: pharmacotherapy
  topic: keywords
subject: pharmacodynamics
  topic: keywords
subject: therapeutic targets
  topic: keywords
creator: Petra Hlauskova
creator: Karel Urbanek
rights: Copyright (c) 2026
date: 2026-04-17
publication date: 2026-04-17
starting page: 150
ending page: 158
doi: 10.48095/ccgh2026150

Impact of successful iron deficiency anemia correction with iron carboxymaltose on quality of life, treatment adherence, and exacerbation frequency in inflammatory bowel dis­ease patients
type: item
description: Background: Iron deficiency anemia (IDA) is a common extraintestinal manifestation of inflammatory bowel dis­ease (IBD) that significantly impairs the quality of life. This study evaluated the efficacy of intravenous iron carboxymaltose (ICM) in correcting IDA and its impact on quality of life, treatment adherence, and dis­ease exacerbation frequency in IBD patients. Methods: A prospective single-center study included 94 adult IBD patients with confirmed IDA. Participants received intravenous ICM (dose calculated by the Ganzoni formula) and were fol­lowed for 6 months. Primary outcomes included hemoglobin (Hb) normalization, quality of life measures (IBDQ questionnaire), treatment adherence, and dis­ease exacerbation rates. Results: ICM administration resulted in significant increases in Hb levels (from 92.1 ± 10.8 g/L to 113.7 ±1 1.0 g/L; P < 0.0001) and serum iron (from 4.6 ± 2.1 µmol/L to 20.3 ± 9.1 µmol/L; P < 0.0001). Quality of life scores improved significantly (IBDQ from 125 ± 24 to 162±19; P < 0.001). Treatment adherence was 89.4%, and IBD exacerbation frequency decreased by 52.3% compared to the pre-treatment period. Conclusion: Successful anemia correction with ICM in IBD patients significantly improves quality of life, enhances treatment adherence, and reduces dis­ease exacerbation frequency, supporting the importance of aggressive anemia management in this population.
subject: Original article
  topic: section
subject: iron deficiency anemia
  topic: keywords
subject: inflammatory bowel dis­ease
  topic: keywords
subject: ferric carboxymaltose
  topic: keywords
subject: treatment adherence
  topic: keywords
creator: Salikhat Dibraeva
creator: Naida Iminova
creator: Ilmuriyat Atasheva
creator: Ravzanat Abdulgamidova
creator: Rukizhat Aigunova
creator: Karina Magomedova
creator: Maryam Abakarova
rights: Copyright (c) 2026
date: 2026-04-17
publication date: 2026-04-17
starting page: 144
ending page: 149
doi: 10.48095/ccgh2026144

Dia­gnosis and therapy of hepatitis B virus infection: Czech national guidelines
type: item
description: The new recommendations reflect the increase in knowledge that has been reported since the release of previous Czech guidelines in September 2017. The base for these guidelines were European Association for the Study of the Liver (EASL) guidelines from May 2025. According to qualified estimates, there are 254 million people with chronic hepatitis B (HBV) infection worldwide. The Czech Republic is among the countries with a low prevalence of HBV infection. HBV infection can cause serious, life-threatening liver damage – fulminant hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). The main goal of treatment is to prolong life and improve its quality by preventing the progression of chronic hepatitis to liver cirrhosis, decompensation of cirrhosis, and the development of HCC. A prerequisite for achieving this goal is sustained suppression of HBV replication. Other treatment goals include preventing vertical transmission of infection from mother to newborn, preventing HBV reactivation, treating extrahepatic manifestations (EHM) of HBV, and reducing the likelihood of HBV transmission between individuals. In general, there are two possible strategies for treating chronic hepatitis B: treatment with nucleos (t) ide analogues (NAs) or pegylated interferon alfa. Currently, the vast majority of patients in the Czech Republic and throughout Europe are treated with NAs. Entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF) should be used as first-line NAs. The main advantage of treatment with highly effective NAs with a high genetic barrier to resistance is predictably high and long-term antiviral efficacy leading to undetectable HBV DNA in serum in the vast majority of adherent patients and the favorable safety profile of these drugs. These NAs can be used to treat any patient with chronic hepatitis B and are the only treatment option for patients with decompensated liver cirrhosis, after liver transplantation, with EHM HBV infection…
subject: Guidelines
  topic: section
subject: chronic hepatitis B
  topic: keywords
subject: entecavir (ETV)
  topic: keywords
subject: tenofovir disoproxil fumarate (TDF)
  topic: keywords
subject: tenofovir alafenamide (TAF)
  topic: keywords
creator: Petr Husa
creator: Jan Sperl
creator: Petr Urbanek
creator: Sona Frankova
rights: Copyright (c) 2026
date: 2026-04-17
publication date: 2026-04-17
starting page: 124
ending page: 143
doi: 10.48095/ccgh2026124

A rare cause of headache in a liver transplant patient – a case report
type: item
description: Invasive fungal infections are among the serious infectious complications in liver transplant recipients, with high morbidity and mortality rates. Aspergillosis is the second most common invasive mycosis, and in most cases, occurs in a disseminated form involving multiple organs. Isolated CNS involvement is considered a rare complication. In this case report, we present a patient who underwent liver transplantation and developed headaches in the early post-transplant period, which were later accompanied by visual disturbances. Several months after the onset of symptoms, a definitive ­gnosis was established only after histological examination of a lesion located on the sphenoid bone of the skull, confirming an infection caused by Aspergillus spp. The patient was started on antifungal therapy according to the infectious dis­ease specialist’s recommendations, with subsequent frequent monitoring of immunosuppressant levels during outpatient fol­low-up.
subject: Case report
  topic: section
subject: liver transplantation
  topic: keywords
subject: invasive fungal infections
  topic: keywords
subject: aspergillosis
  topic: keywords
creator: Natalia Kubanek
creator: Svetlana Adamcova Selcanova
creator: Daniela Zilincanova
creator: Karolina Kristina Sulejova
creator: Daniel Jan Havaj
creator: Adam Halaj
creator: Tomas Koller
creator: Lubomir Skladany
rights: Copyright (c) 2026
date: 2026-04-17
publication date: 2026-04-17
starting page: 118
ending page: 123
doi: 10.48095/ccgh2026118

Neutrophil-to-lymphocyte ratio reflects inflammatory phenotypes of alcohol-associated hepatitis: differences between mild and severe dis­ease
type: item
description: Background and aims: Alcohol-related liver dis­ease (ALD) represents one of the leading causes of advanced chronic liver dis­ease worldwide and is the predominant etiology of cirrhosis in many European regions. Alcohol-associated hepatitis (AH) represents an inflammatory manifestation of ALD and encompasses a wide spectrum of dis­ease severity ranging from mild dis­ease to severe alcohol-associated hepatitis (SAH), which is characterized by intense systemic inflammation and high short-term mortality. The neutrophil-to--lymphocyte ratio (NLR) has emerged as a simple marker of systemic inflammatory activation and has been associated with adverse outcomes in patients with advanced liver dis­ease. However, its distribution across different clinical phenotypes of AH remains insufficiently characterized. The aim of this study was therefore to evaluate differences in NLR values between mild AH and SAH, and to assess the evolution of NLR during hospitalization. Methods: Using our prospective RH7 registry, we analyzed patients hospitalized with cirrhosis and acute decompensation (AD). Among 1,109 patients enrolled in the registry, 283 fulfilled criteria for AD. The mean age of the cohort was 51.3 ± 12.1 years, and 59% were men. ALD was the most frequent etiology of cirrhosis (207 patients, 73.1%). Acute AH was identified as the precipitating event of decompensation in 169 patients. According to dis­ease severity, 37 patients were classified as having mild AH and 132 fulfilled criteria for SAH. NLR was assessed at admission (NLR-0) and on day 7 of hospitalization (NLR-7). Results: Patients with SAH demonstrated significantly higher inflammatory activity compared to those with mild dis­ease. The mean NLR-0 was 4.0 ± 2.5 in the mild AH group and 10.0 ± 9.6 in the SAH group (P < 0.001). Similar differences were observed on day 7 of hospitalization, when the mean NLR-7 was 2.9 ± 1.8 in mild AH and 9.8 ± 8.6 in SAH (P < 0.001). NLR values remained consistently higher in patients w…
subject: Original article
  topic: section
subject: alcohol associated liver dis­ease
  topic: keywords
subject: severe alcoholic associated hepatitis
  topic: keywords
subject: neutrophil-to-lymphocyte ratio
  topic: keywords
creator: Daniela Zilincanova
creator: Svetlana Adamcova Selcanova
creator: Daniela Havaj
creator: Karolina Sulejova
creator: Natalia Kubanek
creator: Michaela Mihokova
creator: Miroslav Vybostok
creator: Michal Zilincan
creator: Roman Zahorec
creator: Peter Jarčuška
creator: Lubomir Skladany
rights: Copyright (c) 2026
date: 2026-04-17
publication date: 2026-04-17
starting page: 111
ending page: 117
doi: 10.48095/ccgh2026111

Donation after Circulatory Death (DCD) – The Need for Programme Implementation in Slovakia
type: item
description: The shortage of donor organs represents one of the major limiting factors in liver transplantation and significantly contributes to mortality among patients on waiting lists. Donation after circulatory death (DCD) has become an established component of transplantation programs in many European countries over the past decades, representing an important opportunity to expand the donor pool. Historically, liver transplantation from DCD donors has been associated with a higher risk of ischemia – reperfusion injury and biliary complications. However, the introduction of modern machine perfusion techniques – particularly normothermic regional perfusion (NRP) and ex vivo machine perfusion (HOPE, NMP) – has significantly improved clinical outcomes and enabled graft survival comparable to transplantation from donors after brain death. Implementation of a DCD program could therefore substantially expand the donor pool in Slovakia, increase transplantation activity, and contribute to reducing mortality among patients on the waiting list.
subject: Review article
  topic: section
subject: donation after circulatory death (DCD)
  topic: keywords
subject: machine perfusion
  topic: keywords
subject: donor pool expansion
  topic: keywords
subject: liver transplantation
  topic: keywords
creator: Svetlana Adamcova Selcanova
creator: Daniela Zilincanova
creator: Lubomir Skladany
rights: Copyright (c) 2026
date: 2026-04-17
publication date: 2026-04-17
starting page: 104
ending page: 110
doi: 10.48095/ccgh2026104

Benefits and risks of HCV cure
type: item
description: Chronic hepatitis C virus (HCV) infection remains a major cause of liver-related morbidity and mortality worldwide. The natural course of HCV infection is highly variable, ranging from asymptomatic dis­ease to significant fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). The advent of direct-acting antivirals (DAAs) has revolutionized HCV treatment, achieving sustained virologic response (SVR) rates exceeding 95% across all stages of liver dis­ease. Viral eradication is associated with reduced liver inflammation, regression of fibrosis, and reduced portal hypertension. More importantly, SVR significantly reduces the risk of liver decompensation, HCC, and liver dis­ease-related mortality. However, the risk of HCC is not entirely eliminated, particularly in patients with advanced fibrosis or cirrhosis, and therefore, HCC surveillance is recommended. DAA therapy has also made it possible to treat patients with decompensated cirrhosis, leading to improved liver function, and in selected cases, removal of the patient from the liver transplant waiting list. However, treatment response and clinical course depend on baseline liver function; in patients with advanced dis­ease (MELD score ≥ 20), the chance of achieving SVR is lower, with a higher risk of adverse events. Even after achieving SVR, metabolic risk factors, including obesity, betes, and fatty liver dis­ease, may negatively impact further course of the dis­ease and the risk of developing HCC. Weight gain after achieving SVR can be significant and influenced by host genetic factors, such as variants of the PNPLA3 gene.
subject: Review article
  topic: section
subject: HCV infection
  topic: keywords
subject: cirrhosis
  topic: keywords
subject: hepatocellular carcinoma
  topic: keywords
subject: sustained virological response
  topic: keywords
creator: Tomas Nesnidal
creator: Sona Frankova
rights: Copyright (c) 2026
date: 2026-04-17
publication date: 2026-04-17
starting page: 98
ending page: 103
doi: 10.48095/ccgh202698

Editorial 2/2026
type: item
description: Vážení čitatelia, jar sa stretla s jarou a je tu ďalšie vydanie vášho obľúbeného časopisu Gastroenterologie a hepatologie s ťažiskom v hepatológii. Uplynulému roku vo svete dominovali nové aj staré vojny, ktoré zmenili horizont medicíny v nám nepredstaviteľnej miere – okrem iného následkom utajovania zdravotníckych informácií; umlčali múzy a mohli nám pripomenúť Karla Kryla; a, ako prvú popravili pravdu. Decembrové číslo Lancetu nazvalo uplynulý rok Annus horibilis pre zdravie USA – okrem iného kvôli zastaveniu očkovania proti hepatitíde B; British Medical Journal sa s čitateľmi rozlúčil titulkom Goodbye to the year of the Big Lie a slovami: „Žijeme vo svete lží, zatrolených lží a AI halucinácií… prezident Trump ich počas prvého volebného obdobia vyslovil 30 573.“ Ktovie, či by Thierry Poynard nazval aj dnes, po štvrťstoročí, svoj článok Truth Survival in Clinical Research: An Evidence-Based Requiem. A ktovie, či by mu polčas pravdy o cirhóze a hepatitídach vyšiel inak, než 45 rokov. Za hepatológiu sme sa to sčasti dozvedeli na ôsmom kvinkvenále Baveno VIII, ktoré sa konalo 27.–28. 3. a ukázalo, že sa veľká časť odporúčaní pre endoskopickú gastroenterológiu za 5 rokov v podstate nezmenila (baveno8.org). Hepatológia sa od minulého, covidového online Bavena posunula k neinvazívnej ­gnostike portálnej hypertenzie, ku s tým súvisiacim novým cieľovým premenným pre manažment pacientov aj pre klinický výskum a k ich personalizácii podľa etiológie. Hlavne v súvislosti s tsunami MASLD (metabolic dysfunction-associated steatotic liver dis­ease). Veľmi zaujímavé pre bežnú klinickú prax aj patogeneticky zameraný výskum boli výsledky štúdií, v ktorých efektivita kauzálnej (na etiológiu zameranej) liečby nekorelovala vždy s poklesom portálnej hypertenzie. Po 10 rokoch od prvého návrhu sa pre klinickú prax namiesto pojmu cirhóza (tam, kde nie je histologický dôkaz, čo je vďaka NIT [neinvazívne testy na ­gnostiku – predovšetkým – fibrózy] čoraz častejšie) definitívne ustaľuje pojem…
subject: Editorial
  topic: section
creator: Lubomir Skladany
rights: Copyright (c) 2026
date: 2026-04-17
publication date: 2026-04-17
starting page: 91
ending page: 91
doi: 10.48095/ccgh202691

Let‘s go beyond the limits of Crohn‘s disease treatment – simply, subcutaneously
type: item
description: Během edukačního sympozia pořádného společností Johnson & Johnson 29. ledna 2026 v Praze u příležitosti stanovení úhrady guselkumabu v léčbě Crohnovy nemoci v ČR byly představeny aktuální poznatky o možnostech cílené léčby tohoto onemocnění se zaměřením na osu interleukinu 23. Zazněly patofyziologické souvislosti, klinická data z programů GALAXI a GRAVITI i praktické zkušenosti z českého klinického prostředí.
subject: Commercially supported communications
  topic: section
creator: Michaela Bachrata
rights: Copyright (c) 2026
date: 2026-02-22
publication date: 2026-02-22
starting page: 79
ending page: 83

The time has come for a paradigm shift in the care of patients with IBD in the Czech Republic
type: item
description: Sympozium pořádané v rámci programu loňského 8. kongresu České gastroenterologické společnosti, které bylo podpořeno společností Takeda, nebylo věnováno konkrétnímu léku. Zato poskytlo unikátní prostor k pojmenování zásadních problémů, které léčbu pacientů s idiopatickými střevními záněty (IBD) v ČR provázejí.
subject: Commercially supported communications
  topic: section
creator: Jan Kulhavý
rights: Copyright (c) 2026
date: 2026-02-22
publication date: 2026-02-22
starting page: 73
ending page: 77

The selection from international journals 1/2026
type: item
description: The selection from international journals
subject: Comments
  topic: section
rights: Copyright (c) 2026
date: 2026-02-22
publication date: 2026-02-22
starting page: 70
ending page: 71

Recurrent bleeding from a Dieulafoy’s lesion of the cecum – a case report
type: item
description: We present a case report of recurrent bleeding from a Dieulafoy’s lesion in the cecum. This is a rare cause of bleeding into the lower gastrointestinal tract, clinically manifesting from minor to massive bleeding with the development of severe microcytic anemia requiring hospitalization and blood transfusion. Diagnosis and therapy are based on endoscopic examination of the lower digestive tract and are considerably limited by the intermittent nature of the bleeding, which often results in false negative findings. Treatment is based on achieving hemostasis utilizing endoscopic methods such as adrenaline injection, argon plasma coagulation, and using hemoclips. Only a few case reports of Dieulafoy’s lesions in the colon have been described in the available literature. Even though the lesion is rare, it is necessary to consider it in the differential diagnosis of anemia, especially in cases with negative results of the initial endoscopic examination.
subject: Case report
  topic: section
subject: endoscopy
  topic: keywords
subject: Dieulafoy’s lesion
  topic: keywords
subject: bleeding
  topic: keywords
subject: colon
  topic: keywords
creator: Martin Tomas
creator: Petr Hribek
creator: Tomas Grega
creator: Zuzana Vackova
creator: Jan Csomor
creator: Stepan Suchanek
creator: Petr Urbanek
rights: Copyright (c) 2026
date: 2026-02-22
publication date: 2026-02-22
starting page: 65
ending page: 68
doi: 10.48095/ccgh202665

The interplay between oral health and gastrointestinal disorders: a comprehensive narrative review of emerging links and clinical implications
type: item
description: Emerging evidence suggests a bidirectional relationship between oral health and gastrointestinal (GI) disorders, yet this connection remains inadequately understood in clinical practice. This comprehensive narrative review examines the current evidence linking oral microbiome dysbiosis, periodontal disease, and other oral health parameters with various GI disorders. Our review identified significant associations between periodontal disease and increased risk of inflammatory bowel disease (IBD) and colorectal cancer. Oral microbiome dysbiosis, characterized by increased abundance of pathobionts including Porphyromonas gingivalis and Fusobacterium nucleatum, was linked to exacerbation of IBD symptoms and intestinal inflammation. Additionally, gastroesophageal reflux disease (GERD) demonstrated significant correlations with dental erosion, periodontitis, and oral mucosal lesions. Mechanistic studies suggest that oral-gut translocation of bacteria, systemic inflammatory mediators, and shared immune dysregulation may underlie these associations. Conclusions: This review highlights the significant interplay between oral health and GI disorders, emphasizing the potential for integrated clinical approaches. Recommended clinical implications include comprehensive oral health assessment in patients with GI disorders, periodontal therapy as an adjunctive treatment strategy, and interdisciplinary collaboration between gastroenterologists and dental professionals. Further prospective longitudinal studies and clinical trials are warranted to establish causality and develop evidence-based integrated treatment protocols.
subject: Review article
  topic: section
subject: ulcerative colitis
  topic: keywords
subject: Crohn’s disease
  topic: keywords
subject: gastrointestinal disorder
  topic: keywords
subject: oral manifestations
  topic: keywords
creator: Sowmya Halasabalu Kalgeri
creator: Sunil Kumar Bheemasamudra Balaraj
creator: Vidya Gowdappa Doddawad
creator: Ashwini Tumkur Shivakumar
creator: Anupama Aradya
creator: R Sumukh Bharadwaj
rights: Copyright (c) 2026
date: 2026-02-22
publication date: 2026-02-22
starting page: 54
ending page: 64
doi: 10.48095/ccgh202654

Gastrointestinal bleeding in patients with chronic kidney disease
type: item
description: Gastrointestinal bleeding (GIB) occurs more frequently and has greater clinical impact in patients with chronic kidney disease (CKD) than in patients without kidney disease. Current data prove that advanced stages of CKD, especially chronic renal failure (CRF), are independent risk factors for GIB. Hemodialysis treatment is a specific independent factor for GIB in CKD patients. Increased risk of GIB in CKD patients manifests by higher incidence and length of hospitalizations and higher mortality. The clinical condition of patients with advanced CKD and especially with CRF is usually more serious compared with patients without kidney disease. Moreover, it has been shown that the ability to provide these patients with an efficient treatment, especially early endoscopy, is decreased, which is partly associated with increased mortality. These findings suggest that greater attention should be paid to the topic of GIT in order to improve the outcomes and decrease the mortality of these patients.
subject: Review article
  topic: section
subject: chronic kidney disease
  topic: keywords
subject: hemodialysis
  topic: keywords
subject: gastrointestinal bleeding
  topic: keywords
subject: endoscopy
  topic: keywords
subject: mortality
  topic: keywords
creator: Miroslav Merta
rights: Copyright (c) 2026
date: 2026-02-22
publication date: 2026-02-22
starting page: 49
ending page: 53
doi: 10.48095/ccgh202649

Current status and prospects of personalized medicine in patients with inflammatory bowel disease
type: item
description: Introducing new drugs in Crohn’s disease and ulcerative colitis has been a regular and broad framework in the last few years. Since 2024, monoclonal antibodies targeting IL-23 are particularly associated with robust expectations. Currently, we have no relevant biological, genetic or molecular markers for disease and therapeutic prognostication. Promising approaches might be in tight monitoring of therapeutic trajectories and searching for minimal residual histologic disease parameters. Patients with a very prompt and fast therapeutic response after therapy initiation have better long-term outcomes in terms of sustained remission and normalisation of quality of life.
subject: Review article
  topic: section
subject: Crohn’s disease
  topic: keywords
subject: ulcerative colitis
  topic: keywords
subject: advanced therapy
  topic: keywords
subject: therapeutic trajectories
  topic: keywords
subject: biomarkers
  topic: keywords
creator: Milan Lukas
rights: Copyright (c) 2026
date: 2026-02-22
publication date: 2026-02-22
starting page: 44
ending page: 48
doi: 10.48095/ccgh202644

Rare extraintestinal involvement in IBD – a case report
type: item
description: Crohn’s disease is a chronic inflammatory disease affecting various locations of the gastrointestinal tract, sometimes involving other organ systems. The article illustrates a case of a patient who presented with an extremely rare laryngeal involvement in Crohn’s disease followed by a consecutive multidisciplinary therapeutic approach.
subject: Case report
  topic: section
subject: Crohn’s disease
  topic: keywords
subject: laryngitis
  topic: keywords
subject: extraintestinal manifestations
  topic: keywords
subject: infliximab
  topic: keywords
subject: ustekinumab
  topic: keywords
creator: Milan Hlista
creator: Matej Hlista jr.
rights: Copyright (c) 2026
date: 2026-04-27
publication date: 2026-04-27
starting page: 39
ending page: 43
doi: 10.48095/ccgh202639

Risk of acute pancreatitis in patients with inflammatory bowel disease
type: item
description: Acute pancreatitis is more prevalent in inflammatory bowel disease (IBD) patients in comparison with the healthy population. The most frequent cause of acute pancreatitis in IBD patients is medication therapy, especially with thiopurines and mesalazine, and rarely due to other medications. Symptomatology of acute pancreatitis might by caused by a 2nd type of autoimmune pancreatitis, which is associated more frequently with ulcerative colitis. Cholethiasis is more prevalent in patients with Crohn’s disease due to malabsorption of bile acids after ileo-colonic resection. There is a reason that acute biliary pancreatitis is more prevalent in Crohn’s disease patients compared to ulcerative colitis. In most cases, the course of acute pancreatitis in the IBD population is mild with edematous structural changes in the pancreas, which can be completely resolved.
subject: Review article
  topic: section
subject: inflammatory bowel disease
  topic: keywords
subject: ulcerative colitis
  topic: keywords
subject: Crohn’s disease
  topic: keywords
subject: acute pancreatitis
  topic: keywords
subject: autoimmune pancreatitis
  topic: keywords
creator: Petr Dite
creator: David Solil
creator: Magdalena Uvirova
creator: Tomas Kupka
creator: Michal Konecny
creator: Jiri Dolina
creator: Bohuslav Kianicka
rights: Copyright (c) 2026
date: 2026-04-27
publication date: 2026-04-27
starting page: 36
ending page: 38
doi: 10.48095/ccgh202636

Subcutaneous infliximab CT-P13 as second-line treatment after failure of anti-TNF therapy in patients with Crohn’s disease
type: item
description: This pilot, prospective, observational two-center study evaluated the efficacy and safety of subcutaneous infliximab CT-P13 S.C. as a second-line treatment in patients with moderate-to-severe Crohn’s disease who had experienced treatment failure with previous intravenous infliximab or adalimumab therapy. Sustained therapeutic response after switching administration methods was observed in 70% of patients, while plasma infliximab concentrations during subcutaneous administration reached more than three-fold higher levels compared with baseline. Half of the patients who exhibited signs of disease activity at the time of treatment transition achieved complete clinical remission. Treatment was discontinued prematurely in 30% of patients due to lack of efficacy or adverse events.
subject: Original article
  topic: section
subject: Crohn’s disease
  topic: keywords
subject: biological therapy
  topic: keywords
subject: infliximab CT-P13 S.C.
  topic: keywords
creator: Martin Kolar
creator: Milan Lukas
creator: Dana Duricova
creator: Katerina Vlkova
creator: Anna Gojdicova
creator: Tibor Hlavaty
creator: Karin Cerna
creator: Martin Lukas
rights: Copyright (c) 2026 Gastroenterologie a hepatologie
date: 2026-04-27
publication date: 2026-04-27
starting page: 30
ending page: 35
doi: 10.48095/ccgh202630

Quality of life of patients with inflammatory bowel disease in the Czech Republic
type: item
description: Introduction: Normalization of the quality of life is an important therapeutic goal in patients with inflammatory bowel disease (IBD). Aim: To evaluate the quality of life in patients with IBD in the Czech Republic. Methods: The study involved patients with IBD aged ≥ 18 years who were approached through gastroenterology departments in the Czech Republic and online through a patient organization. Patients completed a one-time, anonymous questionnaire focusing on various aspects of the quality of life. Results: The study was conducted between September 2024 and May 2025 involving 1,272 patients (60% with Crohn‘s disease, 58% women, median age 39 years, and 60.3% on biological therapy). The most commonly reported problem associated with IBD was fatigue (82.5%), followed by gastrointestinal symptoms and extraintestinal manifestations. Up to 40% of respondents reported psychological problems (anxiety and depression). Approximately two-thirds of patients (57–69%) admitted to at least occasional restrictions in social activities such as travelling, playing sports, or eating in public places. Two-thirds of respondents (72.1%) stated that they work full-time or part-time, and 20.1% admitted to receiving disability pension. Targeted therapy – biologics and small molecules (OR 1.74; 95% CI 1.25–2.45), Crohn‘s disease (OR 1.48; 95% CI 1.09–2.03), and relapse frequency ≥ 1 per year (OR 2.73; 95% CI 2.02–3.72) increased the risk, while higher education (OR 0.48; 95% CI 0.34–0.66) reduced the risk of disability. Conclusion: This study highlighted the negative impact of IBD on various aspects of patients‘ lives, particularly their personal and professional lives, and the high incidence of mental health problems among IBD patients.
subject: Original article
  topic: section
subject: iinflammatory bowel diseases
  topic: keywords
subject: quality of life
  topic: keywords
subject: Crohn’s disease
  topic: keywords
subject: ulcerative colitis
  topic: keywords
subject: biological products
  topic: keywords
subject: patient reported outcome
  topic: keywords
subject: measures
  topic: keywords
subject: depression
  topic: keywords
subject: employment
  topic: keywords
creator: Petra Minarikova
creator: Petra Matejkova
creator: Ivan Kuzko
creator: Martina Pfeiferova
creator: Lenka Slaba
creator: Dana Duricova
rights: Copyright (c) 2026
date: 2026-02-22
publication date: 2026-02-22
starting page: 22
ending page: 29
doi: 10.48095/ccgh202622

Medical therapy of ulcerative colitis: updated guidelines of the Working group for IBD
type: item
description: Pracovní skupina pro idiopatické střevní záněty (PS IBD) České gastroenterologické společnosti přináší v následujícím textu aktualizovaná doporučení pro medikamentózní léčbu ulcerózní kolitidy (UC). Tato doporučení zahrnují přehled léků konvenčních i medikamentů označovaných jako pokročilá (advanced) nebo též cílená léčba. Její rychlý rozvoj v posledních letech dále akceleroval a přinesl nové možnosti pacientům, u nichž konvenční léčiva selhávají nebo nejsou tolerována. Aktualizovaná doporučení jsou ve srovnání s předchozími [1] textem stručnějším a více zaměřeným na praktické informace o léčbě. Užitečnou pomůckou by pro čtenáře měl být závěrečný algoritmus, který shrnuje současné poznatky a zkušenosti expertů PS IBD v oblasti cílené terapie UC. Praktickou stránku textu podtrhuje i rozdělení cílené léčby na léky první linie a vyšších linií tak, jak stanovují aktuální úhradové podmínky Státního ústavu pro kontrolu léčiv (SÚKL). Do textu jsme nezařadili část věnovanou léčbě IBD v graviditě a laktaci, toto téma bude publikováno v samostatném článku v některém z dalších čísel časopisu. Narůstající potřeba moderní léčby spolu s dramaticky stoupajícími počty pacientů s UC v České republice vyžadují zapojení stále většího počtu aktivních gastroenterologů a zájemců o problematiku IBD. Právě jim je následující text určen především.
subject: Guidelines
  topic: section
creator: Martin Bortlik
creator: Dana Duricova
creator: Ondrej Hradsky
creator: Milan Luk
creator: Lucie Prokopova
creator: P. Moravkova
creator: Tomas Douda
creator: Pavel Drastich
creator: Zuzana Serclova
creator: Petra Minarikova
creator: Petra Matejkova
creator: M. Tomanova
creator: Ales Novotny
creator: Tomas Drasar
creator: Jana Kozeluhova
creator: Mojmir Kasalicky
creator: Eva Koblihova
creator: O. Fabian
creator: L. Bajer
creator: S. S. Rajpoot
creator: Pavel Kohout
creator: Barbora Pipek
creator: M. Lengalova
rights: Copyright (c) 2026
date: 2026-04-27
publication date: 2026-04-27
starting page: 14
ending page: 21
doi: 10.48095/ccgh202614

Unexpected cause of overall deterioration in the patient’s condition
type: item
description: Muž (79 let) byl přivezen záchrannou službou na urgentní příjem pro celkové zhoršení stavu a slabost trvající asi 14 dní. Anamnestické údaje zahrnovaly nikotinizmus, CHOPN, hypertenzi, hyperlipidemii, diabetes mellitus 1. typu, obezitu. Pacient dlouhodobě užíval antihypertenziva, statin, inzuliny, NSA (Meloxicam) při bolesti – užíval jej maximálně 1× denně. Mezi subjektivními obtížemi dominovaly řadu dnů trvající obtíže – celková slabost, únava, udával také bolesti v pravém podžebří a zvracení. Objektivně bylo břicho bolestivé v pravém epigastriu, ve stejném místě byla hmatná i tuhá rezistence. Laboratorně jsme zjistili hyperglykemii 18,6 mmol/l, minerálový rozvrat – hyponatremii 125 mmol/l, hyperkalemii 5,6 mmol/l, známky dehydratace renální insuficience – urea 23,8 mmol/l, kreatinin 316 umol/l, laktát 3,2 mmol/l. Byla přítomna zvýšená zánětlivá aktivita, CRP 90 mg/l. V krevním obraze dominovala těžká anemie (Hgb 50 g/l), trombocytóza 676 × 109/l, byla přítomna spontánní koagulopatie. Hodnoty jaterních testů byly v normě. Provedli jsme sonografii břicha s nálezem hydropsu žlučníku se sludge, konkrementy v krčku žlučníku, gastrektazie. Pacientovi jsme zavedli nazogastrickou sondu, která odvedla 1 000 ml stagnačního obsahu. K dalšímu objasnění patologie bylo provedeno nativní CT břicha (zvýšená hladina kreatininu). Pacienta jsme po konzultaci s radiologem a chirurgem indikovali k operačnímu výkonu.
subject: Kvíz z klinické praxe
  topic: section
creator: Ivana Rucklova
rights: Copyright (c) 2026
date: 2026-04-27
publication date: 2026-04-27
starting page: 11
ending page: 11

The sooner, the better
type: item
description: Vážení čtenáři časopisu Gastroenterologie a hepatologie, po roce opět otevíráte první číslo našeho časopisu věnované především idiopatickým střevním zánětům (IBD). Crohnova choroba (CN) i ulcerózní kolitida (UC) tvoří sice relativně malou, ale zato velmi pestrou, a především nesmírně dynamickou oblast současné gastroenterologie. Dokladem toho je i aktuální číslo, které přináší řadu zajímavých článků s tematikou IBD. Základem léčby IBD je dlouhodobá, často celoživotní terapie medikamentózní. Její efektivita, a také bezpečnost jsou proto klíčovým faktorem, který osud pacientů ovlivňuje. V tomto čísle nabízíme aktualizovaný přehled medikamentózní léčby UC, který zahrnuje všechny dostupné léky a nabízí také praktické informace k jejich použití u pacientů s tímto onemocněním [1]. Klinický výzkum reprezentují dvě práce. První z nich představuje výsledky rozsáhlé dotazníkové akce, kterou ve spolupráci s pracovní skupinou IBD zorganizovala pacientská organizace Pacienti IBD [2]. Tato práce navazuje na starší průzkum podobného charakteru, cílem bylo posoudit vývoj v oblasti kvality života pacientů. Výsledky jednoznačně potvrzují vysokou zátěž, kterou IBD do života pacientů přináší a s níž se potýkají navzdory stále více používané biologické, resp. cílené léčbě. Druhá práce je pilotním česko-slovenským projektem, jehož cílem bylo posoudit efektivitu a bezpečnost subkutánního infliximabu ve druhé linii u pacientů s CN, u nichž nebylo dosaženo uspokojivé hladiny léku, nebo u nich tato léčba selhávala [3]. Studie ukázala, že subkutánní infliximab je efektivní variantou léčby u této skupiny pacientů s velmi dobrou perzistencí terapie. Personalizovaná medicína je „svatým grálem“ současné medicíny, IBD nevyjímaje. Hledání prediktorů, markerů a dalších faktorů vedoucích k efektivnější a bezpečnější léčbě je nejspíše nekonečným příběhem. Jeho část související s problematikou IBD shrnuje článek prof. Lukáše [4]. V této souvislosti musím zmínit, že zatím nejnadějnějším pokusem o prolom…
subject: Editorial
  topic: section
creator: Martin Bortlik
rights: Copyright (c) 2026
date: 2026-04-27
publication date: 2026-04-27
starting page: 4
ending page: 4

Editorial 1/2026
type: item
description: Vážené čtenářky, vážení čtenáři, vítám vás do jubilejního ročníku časopisu Gastroenterologie a hepatologie, který v letošním roce slaví úctyhodný 80. ročník od prvního vydání v dubnu 1947 pod názvem Gastro-enterologia Bohema. Časopis v průběhu osmi dekád prošel mnohými změnami, měnil své tituly a v jeho vedení se vystřídalo celkem šest šéfredaktorů, mezi nimiž vyčnívá Zdeněk Mařatka, jenž vedl tento časopis neuvěřitelných 30 let. Přes všechny změny, které zahrnovaly také střídání vydavatelů, změny formátu a grafické podoby, si udržel roli prezidiálního časopisu pro obory gastroenterologie a hepatologie. Na svých stránkách přináší platformu pro další vzdělávání, dává možnosti komunikace z odborné praxe a vytváří vhodné prostředí pro prezentaci výsledků klinického a experimentálního výzkumu. V současné době je distribuován nejen v Česku, ale také na Slovensku a je časopisem čtyř odborných společností, jež s hrdostí uvádíme na titulní straně. S ohledem na 80. ročník jsme se snažili trochu upravit titulku časopisu. Novinkou v tomto ročníku bude zavedení kompletní anglické mutace časopisu, takže každé číslo bude mít v internetové podobě na www.csgh.info anglickou verzi. V průběhu roku 2026 dojde také k významné úpravě webových stránek časopisu. To, co se osvědčilo v minulosti, zůstává v platnosti i tento rok. Preferenční zaměření každého čísla na různé segmenty gastroenterologie, hepatologie a digestivní endoskopie se stalo již tradicí a probíhá nepřetržitě od roku 2011. V prvním čísle bude hlavní pozornost zaměřena na problematiku IBD, ve druhém čísle na hepatologii, ve třetím na digestivní endoskopii, čtvrté má hlavní téma experimentální a klinická gastroenterologie, páté gastrointestinální onkologie a poslední, šesté číslo má téma dětská gastroenterologie a bariatrie. Každé nové vydání bude mít svého stabilního koordinátora podle preferenčního tématu. V posledních 2 letech vytváříme před každým číslem krátký podcast, který dostávají všichni členové jednotlivých společ…
subject: Editorial
  topic: section
creator: Milan Lukas
rights: Copyright (c) 2026
date: 2026-04-27
publication date: 2026-04-27
starting page: 3
ending page: 3

8. kongres České gastroenterologické společnosti: abstrakta
type: item
description: 8. kongres České gastroenterologické společnosti ČLS JEP 16.–18. října 2025 Clarion Congress Hotel Prague, Praha
subject: Abstrakta
  topic: section
rights: Copyright (c) 2025
date: 2026-04-14
publication date: 2026-04-14
starting page: 414
ending page: 432